Compare BridgeBio Pharma Inc (BBIO) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs TJX Companies Inc — how do they compare? BridgeBio Pharma Inc trades at $84.7 (market cap $16.46B), while TJX Companies Inc trades at $150.35 (market cap $166.08B). The key difference: TJX Companies Inc is far larger — about 10.1× BridgeBio Pharma Inc's market cap, and TJX Companies Inc pays a 1.28% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TJX | |
|---|---|---|
Market Cap | $16.46B | $166.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $168.41 |
52-Week Low | $44.81 | $121.35 |
Enterprise Value | $18.02B | $174.68B |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
TJX trades at $150.53, down 0.54% today, with strong fundamentals including 8.63% net margin and 61.25% ROE. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate. Technical indicators signal near-term bearish pressure, but analyst consensus remains overwhelmingly bullish with an $181.80 price target. The company maintains robust cash flow from operations at $6.12B in 2025, supporting dividend payments and expansion plans.
Outlook is positive due to earnings momentum and international growth, but risks include valuation premiums (P/E 29.29) and consumer spending sensitivity. The stock offers growth potential if execution continues, though technical weakness may persist short-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
